European drug regulators have determined that new warnings regarding lower limb amputations should be added to the safety labels of type 2 diabetes drugs known as SGLT2 inhibitors. The warning is based on a European Medicine Agency (EMA) review of data from two ongoing clinical trials on SGLT2 inhibitors containing the active ingredient canagliflozin, which includes the brand name drugs Invokana and Invokamet (which sells under the name Vokanamet in Europe). One of the clinical trials is to determine canagliflozin’s impact on patients at high risk for cardiovascular events and the other is to assess affects on the kidneys. In ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.